Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.990 +0.005 (+0.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,379,425
Open 1.940
Bid (Size) 1.980 (1,100)
Ask (Size) 2.030 (800)
Prev. Close 1.985
Today's Range 1.920 - 2.070
52wk Range 0.6600 - 3.535
Shares Outstanding 60,705,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
+18.5%
+18.5%
1 Month
-29.9%
-29.9%
3 Month
+0.5%
+0.5%
6 Month
+112.1%
+112.1%
1 Year
-4.8%
-4.8%

More News

Read More
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗
Via Stocktwits
News headline image
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
News headline image
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss ↗
Via Chartmill
News headline image
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗
Via Benzinga
News headline image
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CRBU DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU
From The Rosen Law Firm PA
Via GlobeNewswire

Frequently Asked Questions

Is Caribou Biosciences, Inc. - Common Stock publicly traded?
Yes, Caribou Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Caribou Biosciences, Inc. - Common Stock trade on?
Caribou Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Caribou Biosciences, Inc. - Common Stock?
The ticker symbol for Caribou Biosciences, Inc. - Common Stock is CRBU on the Nasdaq Stock Market
What is the current price of Caribou Biosciences, Inc. - Common Stock?
The current price of Caribou Biosciences, Inc. - Common Stock is 1.990
When was Caribou Biosciences, Inc. - Common Stock last traded?
The last trade of Caribou Biosciences, Inc. - Common Stock was at 11/14/25 04:00 PM ET
What is the market capitalization of Caribou Biosciences, Inc. - Common Stock?
The market capitalization of Caribou Biosciences, Inc. - Common Stock is 120.80M
How many shares of Caribou Biosciences, Inc. - Common Stock are outstanding?
Caribou Biosciences, Inc. - Common Stock has 121M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.